SAKK 16/14-peripheral Immune Cell Populations in Patients with Stage IIIA (N2) NSCLC and neoadjuvant Immunotherapy with Durvalumab
D. Schmid, M. Trueb, P. Herzig, C. Gartner-Pelham,I Alborelli, K. Leonards, M. Manzo, P. Jermann, S. Savic-Prince,E. Keller, E. Eboulet,S. Hayoz, G. Godar, M. Schneider, A. B. Sobottka-Brillout, M. Nowack, G. Tochtermann,V. H. Koelzer, D. Konig,M. Pless,A. Zippelius, S. Rothschild ONCOLOGY RESEARCH AND TREATMENT（2022）
AI 理解论文
溯源树
样例
